|
|
Article: Other News To Note.
- Article from:
- BIOWORLD Today
- Article date:
- November 4, 2009
CopyrightCOPYRIGHT 2009 A Thomson Healthcare Company. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Antigenics Inc., of New York, said interim Phase I results of the pneumococcal vaccine Quilimmune-P - a combination of a commercially available vaccine plus Antigenics' QS-21 adjuvant - demonstrated that compared to currently available pneumococcal vaccines, Quilimmune-P stimulated significantly higher levels of immune response among elderly adults. The study was described at the fifth annual Vaccine Conference of the National Foundation for Infectious Diseases, held in Baltimore. The five-month trial involved 30 healthy, vaccine-naive subjects over the age of 65.
BioSante Pharmaceuticals Inc., of Lincolnshire, Ill., released at the Association for Research in ...